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Use of marine compounds to treat 
ischaemic diseases 
Catherine Boisson-Vidal, Unité Inserm 1140 Ithem, Faculté de Pharmacie de Paris, Université Paris 
Descartes, Sorbonne Paris Cité, 4 avenue de l’observatoire, 75006 Paris, France. 
1- Abstract 
The marine reservoir, with its massive biodiversity, likely harbours numerous human drug 
candidates. Polysaccharides of various marine origins have shown to be good alternatives to 
mammalian polysaccharides. One well-known example is heparin, a sulphated polysaccharide used in 
the prevention of thrombosis and pulmonary embolism.  
The oldest use of marine polysaccharides concerns those produced by algae. These products form 
the basis for an economically important and expanding global industry. This chapter provides the 
historical background to the discovery of the therapeutic potential of these marine compounds, 
together with their medical and biotechnological applications.  
Peripheral arterial disease (PAD) is a progressive disorder due to atherosclerosis (narrowing of the 
peripheral arteries, especially in the legs). Arterial flow is reduced or discontinuous, causing oxygen 
deprivation in the underlying tissues and possible tissue necrosis. The primary aim of medical therapy 
is to increase arterial flow in the affected limb, in order to relieve pain, heal trophic lesions and avoid 
amputation. Anticoagulant, antithrombotic and antiplatelet agents are used to reduce the risk of 
thrombus formation. Novel treatments such as therapeutic angiogenesis (promotion of new blood 
vessel growth) are in the development phase, with promising preclinical data.  
Fucoidan is a polysulphated L-fucose endowed with biological activities closely related to its chemical 
composition (especially the distribution of sulphate groups along its polyfucose backbone), and to its 
molecular weight. Fucoidans are highly soluble in water, non-toxic and non-immunogenic. Details are 
provided below on its production and characterization, and on the main chemical characteristics that 
influence their biological activities. Fucoidan exhibits venous and arterial antithrombotic properties 
in animal models. In animal experiments, fucoidan promoted the formation of new blood vessels, 
thereby preventing necrosis of ischaemic tissue. Fucoidan also recruits stem cells from bone marrow, 
further accelerating tissue healing. The cellular and molecular mechanisms underlying fucoidan's 
effects on angiogenesis are then addressed, beginning with a brief overview of blood vessel 
formation. Recent advances have been made in understanding how the interactions between these 
polyfucoses and adult stem cells contribute to new blood vessel formation after ischaemic injury, 
notably via carbohydrates located mainly in the basement membrane and cell surface.  
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2- History of natural marine products 
Drug discovery based on naturally occurring molecules in general, and on natural marine products in 
particular, has been undergoing a renaissance in recent years [1]. The relative failure of 
combinatorial chemistry (synthesis)-based drug discovery has stimulated the interest of large 
pharmaceutical companies in natural products which, historically, have been the source of some 50% 
of all drugs. About 70% of Earth’s surface is covered by the oceans, which are estimated to contain 
more than 2 million species, of which only 190 000 have been identified so far [2]. Algal extracts have 
long been used for medicinal purposes, notably in Chinese traditional herbal medicine for at least 
two thousand years [3]. Some 400 species of seaweed are used as a source of food (especially in Asia 
and the Pacific region), feedstock, medicines, fertilizers and industrial raw materials. Some serve as 
vermifuges to expel ascarids, while others are used to cure sprains, rheumatism, goitre, cough, 
asthma and dropsy. Algae have also long been used in the prevention and treatment of cancer.  
Polysaccharides are the main constituents of brown and red marine algae [4]. Seaweed cell walls are 
made up of various polysaccharides (cellulose, alginates, carrageenans and fucans, see box 1) and 
proteins. Carbohydrates, particularly those found on cell membranes, play critical biological roles. 
Defects in either the structure or the expression of carbohydrate-binding proteins are now known to 
play a role in an ever-increasing number of diseases, such as vascular disorders, viral and bacterial 
infections, tumour progression, and metastasis. Marine polysaccharides also display a wide variety of 
biological functions, such as extracellular matrix organization, cell growth and tissue maturation. 
Despite their potential for drug design, very few marine-derived carbohydrates are being developed 
commercially as therapeutics (see box 2). More attention has been paid to the structure and 
composition of these marine carbohydrates during the past 30 years, mainly because they form 
viscous gels in water that remain stable in the presence of many different additives [5,6]. Agar 
derived from the agarose found in the cell walls of red algae is used as a natural vegetable gelatine. It 
is also extensively used as a suspending agent for radiological solutions such as barium sulphate, and 
as a bulk laxative that forms a smooth and non-irritating hydrated bulk in the digestive tract. Agar is 
also used as an ingredient in tablets and capsules, in order to carry and release drugs, as well as in 
wound dressings and biomaterials. Alginate derivatives and carrageenans are widely used in 
toothpaste, soap, ice cream, yoghurt, tinned meat, fabric printing, and a host of other applications.  
Research on fucoidans extracted from brown algae has steadily increased in recent years. Despite a 
wide range of biological activities and the lack of oral toxicity [7,8], fucoidans remain relatively 
unexploited as a source of medicines, because of its heterogeneity. Indeed, it cannot yet be 
synthesized, and obtaining reproducible batches remains highly challenging. Although they have 
been commercially available for half a century, differences in their chemical composition and 
molecular weight between batches has limited pharmaceutical development. The international 
fucoidans market is none the less growing.  
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3- Peripheral arterial disease and cardiovascular risks - Treatments 
and unmet needs 
Peripheral arterial disease (PAD) is characterized by chronic obstruction of arteries that supply 
tissues. The affected tissues suffer from ischemia, and can develop necrosis if blood circulation is not 
quickly re-established, with a risk of losing a limb or its function. PAD is a frequent disease, affecting 
between 1% and 3% of people older than 60 years [9–12]. It results from atherosclerosis, thrombus 
formation or inflammatory processes, and develops in several stages. Critical limb ischemia (CLI) is 
the end-stage of PAD. Severe obstruction of blood flow results in ischemic pain at rest, ulcers, and a 
significant risk of limb loss. Epidemiological studies show that the incidence of PAD increases with 
age, up to 5% beyond 70 years. PAD progresses slowly, but 20% to 30% of patients eventually 
develop CLI (500-1000 per million inhabitants) requiring revascularization or amputation (more than 
5 000 cases yearly in France [13]). About 18% of patients die during the year after CLI onset, and 26% 
require amputation. Surviving patients need special care that is both heavy and costly.  
PAD affects the blood vessels supplying the arms and legs. Normal arteries are lined by a thin layer of 
endothelial cells (endothelium) which help to keep blood flowing. High blood pressure, smoking and 
high cholesterol can damage the endothelium and lead to the formation of atherosclerotic plaque or 
atheroma. The latter results from the invasion and accumulation of white blood cells, and 
proliferation of intimal-smooth muscle cells that create a "fibrofatty" plaque. This plaque can stay 
fixed to the artery wall and slowly grow, or may suddenly rupture, triggering platelet activation and 
aggregation on their exposed surface (Figure 2). Plaque rupture can add coronary artery or 
cerebrovascular disease to the underlying PAD.  
Immobilization, chronic venous insufficiency, and venous blood stasis in the leg increase the risk of 
vein thrombosis associated with PAD [14]. Thrombus formation disrupts blood flow, leading to 
concerted interaction of activated endothelium with neutrophils and platelets, mediated mainly by 
P-selectin expression on endothelial cells.  
Treatment is aimed at correcting the underlying causes of ischemia and at improving the 
vascularization of affected tissues, in order to prevent gangrene and limb loss, and to reduce the risk 
of heart attack and stroke [9,15].  
3.1 Prevention of disease progression 
Treatment focuses first on modifiable risk factors such as hypertension, dyslipidemia and diabetes 
mellitus through lifestyle modifications [9,10,15]. Smoking cessation and exercise programs are 
proposed to alleviate symptoms. Drug treatment may be prescribed: 1) anticoagulants and/or 
antiplatelet/antithrombotic drugs (aspirin, clopidogrel) to prevent thrombus formation due to slow 
blood flow in microvessels [16]; 2) vasodilatory drugs to prevent platelet aggregation (patients with 
PAD have a systemic endothelial dysfunction associated with impaired vasodilation and enhanced 
platelet aggregation [17]; 3) antihypertensive drugs; and 4) cholesterol-lowering drugs [18]. There is 
a strong correlation between high low-density-lipoprotein cholesterol levels and PAD symptoms.  
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3.2 Anticoagulation 
Despite its disadvantages, heparin has been the polysaccharide most widely used to treat venous 
thrombosis for the past 70 years [19]. Heparin is a highly sulphated glycosaminoglycan: 80% of 
glucosamine residues are N-sulphated, and O-sulphate groups are more abundant than N-sulphate 
groups. This mucopolysaccharide mainly exerts its anticoagulant activity by enhancing the inhibitory 
potency of the plasma proteins antithrombin (AT) and heparin cofactor II (HCII), which inhibit serine 
proteases involved in the coagulation pathway, such as thrombin and factor Xa [20]. The 
anticoagulant activity of heparin is due to a specific pentasaccharide sequence which binds with high 
affinity to AT [21].  
3.3 Surgical revascularization 
Between 40% and 60% of patients with CLI may need surgery to inject thrombolytic drugs (urokinase 
or rt-PA to dissolve a thrombus) or to bypass a blocked or narrowed artery with an artificial vessel to 
improve the microcirculation [15,22]. Balloon angioplasty and stenting are proposed to patients with 
short arterial occlusions, as a first-line attempt at limb salvage [22]. When surgical revascularization 
is not feasible, amputation is often the only therapeutic option. No available treatment has so far 
been shown to reduce the amputation rate at 6 month in patients with CLI [23].  
3.4 Novel therapies—therapeutic angiogenesis 
Much research is focused on ways of promoting the development of new blood vessels (therapeutic 
angiogenesis), including gene therapy [24–27] and cell therapy [24,28,29]. Despite encouraging 
phase 2 trials, however, large prospective double-blind trials of a genetic drug coding for a 
proangiogenic growth factor have shown little improvement in the risk of amputation or death 
[9,15,27,30,31].  
3.4.1 Cell therapy 
Cell therapy, which is more promising, consists of local intramuscular injections of autologous bone 
marrow-derived mononuclear cells into the ischemic limb. Several randomized trials are underway to 
test the safety and efficacy of stem cells in the treatment of PAD [11,29,32–34]. 
3.4.2 How do new blood vessels form? 
The formation of new blood vessels involves at least 3 distinct biological processes [35] (Figure 3). 
Angiogenesis refers to the formation of new vessels by “sprouting” from a pre-existing vascular 
network. Arteriogenesis refers to an increase in the wall thickness and luminal diameter of newly 
formed vessels via the recruitment of perivascular and smooth muscle cells. Vasculogenesis is the 
emergence of blood vessels de novo from vascular endothelial progenitor cells known as angioblasts, 
which differentiate into endothelial cells [36]. These three processes probably occur simultaneously 
during new vessel formation in the lower limbs of patients with PAD. Occlusion of an artery causes 
tissue hypoxia, which is a strong stimulus for angiogenesis [37]. Collateral vessels develop 
physiologically in these patients, leading to an increased microvessel density in affected muscles, 
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which can partially compensate for occlusion of the artery but often fails to restore normal flow 
[35,38].  
The discovery in 1997 that adult peripheral blood contains circulating endothelial progenitor cells 
(EPCs) capable of differentiating into endothelial cells provided new insights into vascular biology and 
opened up exciting therapeutic vistas [39–42]. Asahara's team showed the contribution of these cells 
to blood vessel formation at sites of active angiogenesis, and obtained tissue regeneration by 
infusion of autologous EPCs after ischemic injury [43], leading to the concept of therapeutic 
angiogenesis [44]. These bone marrow-derived angiogenic cells are mobilized to the general 
circulation and then recruited to sites of ischemia in response to various stimuli produced by the 
local inflammatory response, including growth factors and cytokines such as vascular endothelial 
growth factor (VEGF), angiopoietin-1, granlulocyte/macrophage colony-stimulating factor (GM-CSF) 
and stromal-derived factor-1 (SDF-1, Figure 3). These angiogenic cells also participate in the 
development of new blood vessels by releasing factors that attract and activate pericytes and 
smooth-muscle cells, which in turn secrete soluble mediators that stimulate the migration and 
differentiation of local endothelial cells [45].  
The ability of EPCs to mobilize and migrate to ischemic sites thus holds promise for this therapeutic 
approach [41,46] (Figure 4). In animals, these immature cells can be mobilized from bone marrow 
into the circulation by treatment with a variety of compounds, including marine polysaccharides [47–
50], but this process becomes less efficient with age [51]. Reduced EPC numbers and functions are 
indicators of severe endothelial lesions in patients with PAD [41,52,53]. 
Stem cells can be derived from bone marrow, peripheral blood or cord blood, but clinical applications 
have been hindered by ethical concerns and by difficulties in harvesting these cells or in safely and 
efficiently expanding them. Infusion of these bone marrow stem cells improved new blood vessel 
formation in animal models of PAD, enhancing collateral vessel formation and blood perfusion and 
permitting limb salvage even after complete vessel occlusion [39,41,42,54]. However, proangiogenic 
approaches have so far given disappointing results in patients with CLI, owing partly to poor 
engraftment and limited differentiation/survival at the ischemic site [9,11,15,51]. Indeed, only a very 
small fraction of transplanted cells are incorporated into new vessels. EPCs isolated from peripheral 
blood of CLI patients have reduced proliferative capacity and increased apoptotic activity, and 
secrete only small amounts of VEGF.  
4- Chemistry 
4.1 Extraction and preparation of low-molecular-weight fucoidan fractions 
Marine algae are immediately dried to reduce spoilage and chemical degradation, and are then 
stored at room temperature. Various extraction methods have been described [55–60]. Isolation and 
purification of fucans generally involves aqueous extraction (hot water, dilute acid (mainly 
hydrochloric or sulfuric acid (pH 2.0) or alkalis), sometimes with extracting agents; fractional 
precipitation with ethanol, lead salts, calcium salts or quaternary ammonium salts; or fractionation 
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on ion-exchange columns [58,61]. Partial fucan degradation may occur, especially at high 
temperatures and acidic pH. Maceration with dilute hydrochloric acid or sulfuric acid removes any 
soluble mineral salts. Phenolic compounds can be removed by preheating with formaldehyde or by 
extraction at pH 6-7.  
The extracts thus obtained contain other polysaccharides (laminaran and alginic acid) and low-
molecular-weight substances (colored materials, phenolic compounds, mannitol, D-glucose and, in 
some cases, myoinositol), as well as fucans of (ascophyllan and sargassan) [56,62]. Pretreatment with 
80% aqueous ethanol before extraction can remove these low-molecular-weight compounds. Crude 
fractions are purified and fractionated with ethanol, ion-exchange chromatography, or gel-filtration 
chromatography. The purification yield varies with the pH of the extracting medium, the 
temperature, and the extraction time.  
Low-molecular-weight fucoidan can then be obtained by acidic hydrolysis [59], or oxidative-reductive 
depolymerisation [63]. The oxidative-reductive process reduces the molecular weight 
(depolymerization) under mild conditions (pH 7, ambient temperature), with high yields.  
4.2 Structural determination 
Fucoidan being a natural product, it is necessary to ensure the characterization and reproducibility of 
the bioactive fraction, although small variations in chemical composition or molecular weight do not 
significantly affect its biological properties. The homogeneity of fucoidan preparations can be 
determined by gel filtration, ion-exchange chromatography and electrophoresis. Fucosidases and 
enzymes that degrade polyanionic polysaccharides are used to establish fucoidan structure and 
structure–activity relationships [64].  
The type of fucoidan, its sulphation and molecular weight, and the conformation of its sugar residues 
all vary across seaweed species and with the period and place of their harvest [56,57,65]. Within a 
given species, the chemical composition of the fucoidan extract depends on the extraction 
conditions. Free fucans released upon cell wall isolation are similar in composition to fucoidan in 
Pelvetia canaliculata, Ascophyllum nodosum, Fucus vesiculosus and Laminaria digitate, and to 
sargassan in Sargassum muticum [66].  
Fucoidan is mainly composed of (13) and  (14) fucosyl units, usually sulphated at position 2 
or 4 (rarely C3), with additional monosaccharides (D-xylose, D-galactose and D-mannose) 
[55,56,67,68]. Chevolot et al. reported that the predominant repeating structure of fucoidan from 
Ascophyllum nodosum is [1→3)-α-L-Fuc(2SO3 - )-(1→4)-α-L-Fuc(2,3diSO3 - )-(1]n [69]. The respective 
molar ratio of sulphate groups to total sugars (including uronic acid) is 3:2, suggesting that three 
moles of sulphate may be attached mainly to two fucose residues in the polysaccharides.  
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5- Biological properties 
5.1 Marine polysaccharides exhibit anticoagulant activity 
Extracts from over 60 species of brown, red and green seaweed have been reported to exhibit 
anticoagulant capacity [5,6,57]. The main active components are sulphated polysaccharides [70], 
although not all sulphated carbohydrates possess anticoagulant activity [56,71,72]. Extracts of brown 
marine algae have higher anticoagulant activity than extracts of red and green marine algae.  
5.1.1 Principle of anticoagulation 
Anticoagulation is achieved mainly by inhibiting thrombin and factor Xa, two serine proteases. This 
can be done by enhancing the activity of the main physiological serine protease inhibitors, namely 
antithrombin (AT) and heparin cofactor II (HCII). In vitro, heparin greatly accelerates the rate of 
thrombin inhibition both by AT and by HCII [19,20]. The mechanism of heparin-catalyzed thrombin 
inhibition by AT and HCII involves the formation of a ternary complex between heparin, proteinase 
inhibitor and proteinase [21].  
5.1.2 Marine polysaccharides have potent anticoagulant properties 
Carrageenans from red algae have been studied more extensively than fucans [57,73]. The 
mechanism of their anticoagulant activity does not involve AT. Even at high dilutions, they exhibit 
significant anticoagulant activity. However, their clinical use is limited by their immunogenicity and 
tendency to gel, due to their structural heterogeneity and very high molecular weight. Agar has 
similar properties [74].  
5.1.3 Fucoidan exhibits venous and arterial antithrombotic properties with no hemorrhagic risk 
In 1957 Springer et al reported that fucans extracted from the brown marine alga Fucus vesiculosus 
had anticoagulant activity in vitro and in vivo [58]. This activity was neutralized by protamine, 
showing the contribution of sulphate groups. Fucoidan was added to the group of heparinoids. The 
anticoagulant activity of fucoidan correlates with the chemical composition of the different fractions 
[7,57,67,75]. Anticoagulant activity is mainly related to a heparin-like effect on AT and HCII, and to 
direct interaction with thrombin [76,77] (Figure 5). It correlates mainly with the molecular weight 
distribution, the sulphate group content and, probably, the structure of the fucoidan. The negative 
charge density of fucoidan is required for the expression of its antithrombin activity mediated by 
HCII.  
Fucoidan exhibits venous and arterial antithrombotic properties in experimental animals [65,67,78] 
and, contrary to heparin, does not significantly increase the risk of bleeding. It increases the 
antithrombin activity of the protease nexin-1 (PN-1), a pericellular serpin expressed by vascular cells, 
and thereby significantly reduces circulating levels of thrombin by catalysing its inhibition [79]. 
Fucoidan also promotes fibrinolysis by potentiating plasminogen activators and reducing 
plasminogen activator inhibitor-1 (PAI-1) release by endothelial cells [80,81].  
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5.2 Marine polysaccharides have angiogenic properties 
Several sulphated polysaccharides, including heparin, structural mimics of heparan sulphate, and 
carrageenans, have been found to inhibit angiogenesis in vitro, usually through a direct effect on 
endothelial cells when added to the experimental medium [19,47,75]. These properties are due in 
part to the capacity of these polyanions to bind to the heparin-binding site of proangiogenic growth 
factors (mainly VEGF and basic fibroblast growth factor (FGF2)) via their sulphate groups. Commercial 
high-molecular-weight (HMW) fucoidan reduced neovascularization and suppressed tumour 
angiogenesis in experimental models by triggering endothelial cell apoptosis [68]. These effects are 
related to both the sulphation ratio and the molecular weight.  
5.2.1 Contrary to other polysaccharides, fucoidan potentiates angiogenesis in vitro and in vivo 
Fucoidan pretreatment of cultured human umbilical vein endothelial cells (HUVEC) or EPCs for 36 to 
72 hours enhances FGF-2-dependent angiogenesis in vitro [82,83], while the addition of fucoidan 
directly to the culture medium inhibits growth-factor-induced vascular tube formation by endothelial 
cells [47,84]. Fucoidan prestimulation enhances various angiogenic processes, namely cell 
recruitment to ischemic tissue via enhanced EPC adhesion to activated endothelium; MMP-9 
metalloproteinase secretion; extravasation; and differentiation into a vascular network (Figure 6). 
The beneficial effect of EPC infusion in a mouse model of hindlimb ischemia was significantly 
amplified by fucoidan stimulation, preventing tissue necrosis [85] (Figure 7). Fucoidan can also 
promote new blood vessel formation when infused intramuscularly, either alone or together with the 
proangiogenic growth factor FGF-2 [86]. Fucoidan induced an 87% reduction in necrosis and a 75% 
improvement in muscle preservation on day 14, as compared to saline alone [85]. Intravenous 
fucoidan infusion had protective effects in rat models of myocardial ischemia [87]. This protection 
was associated with enhanced neoangiogenesis and a reduction in rhabdomyolysis. During ischemia, 
muscle destruction causes permeabilization of muscle fibres and the release of their contents, 
including enzymes such as CPK, into the bloodstream. Bolus administration of fucoidan induced a 
70% reduction in CPK activity as compared with normal saline. None of the mice treated with 
fucoidan presented necrosis of the fingers or legs, contrary to saline-treated controls [85].  
Fucoidan also inhibits smooth muscle cell proliferation in vitro [88,89] and in vivo [90,91]. Its injection 
prevented neointima formation in an injured thoracic aorta rat model, and after stenting in the 
rabbit iliac artery angioplasty model. Fucoidan stimulated the formation of an endothelial cell lining 
in vascular allografts after 1 month of treatment [92]. Injection of crude heparin and LMW heparin in 
the same experimental conditions did not induce angiogenesis [47,86].  
5.2.2 Injections of LMW fucoidan induce rapid mobilization of stem cells from bone marrow 
Intraperitoneal (IP) or intramuscular injections of LMW fucoidan (5 mg/kg/day) induce rapid 
mobilization of immature progenitors from bone marrow, about as potently as VEGF (0.5 µg/kg/day) 
[47]. Circulating numbers of progenitor cells are significantly increased in peripheral blood of 
fucoidan-treated animals. Stem cell mobilization is also observed after oral fucoidan ingestion [7,93]. 
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This mobilization correlates with the release of GAG-bound SDF-1 from its tissue storage sites into 
the circulation on fucoidan administration.  
Tissue ischemia is accompanied by inflammation, and fucoidan has been shown to possess anti-
inflammatory properties [7,56,67,94]. Daily subcutaneous injection of fucoidan protected 
parenchymal tissue against inflammatory processes and myofibroblastic remodelling in a rat cardiac 
allograft model [95]. It reduced neutrophil, macrophage and CD4+ T cell infiltration at sites of 
inflammation, and improved myocardial status after ischemia/reperfusion injury [7]. These 
antiinflammatory activities correlated with a reduction in tissue expression of transforming growth 
factor beta (TGF) and IL-10. Fucoidan down-regulated the expression of inducible iNOS (that inhibits 
nitric oxide production) and cyclooxygenase 2 (COX2) protein and mRNA levels.  
5.3 What is the fucoidan mechanism of action?  
5.3.1 Cellular and molecular mechanisms underlying fucoidan proangiogenic activity 
The effects of fucoidan appear to be mediated mainly by its charge density, molecular weight and 
degree of sulphation, rather than by a specific carbohydrate structure [69]. Fucoidan shares several 
characteristics with HSPGs. The structural requirements for its interaction with coagulation factors 
and target proteases depend on the proportions and/or distribution of sulphated groups along the 
fucose backbone, and on the saccharide chain composition [96]. Fucoidan fractions presenting slight 
differences in their sulphation pattern differ in their anticoagulant and antithrombotic activities 
[65,97]. Sulphation is critical for fucoidan activity, but sulphate groups alone are unlikely to be 
responsible for the observed biological properties. The fucosyl backbone may also be important. 
Fucosylated chondroitin sulphate species, made up of alternating -D-glucuronic acid and N-acetyl--
D-galactosamine units with branches of sulphated fucose, enhance FGF-2-induced tubular 
morphogenesis in vitro and also trigger an increase in blood SDF-1 levels and immature cell 
mobilization. Like fucoidan, these chondroitin sulphate species that bear sulphated fucose chains 
express antithrombotic activity in experimental animals with venous and arterial thrombosis. 
Branched sulphated fucoses are the key motif responsible for this activity, as shown by comparing 
native and chemically modified defucosylated and/or desulphated chondroitins. The number of 
sulphate groups, and the nature of the molecular backbone, significantly influence the biological 
properties of these compounds [96].  
5.3.2 Fucoidan modulates the biological activity of angiogenic heparin-binding proteins 
Of particular interest, fucoidan partially restores the adhesion of cultured progenitor cells to 
activated endothelium after their treatment with enzymes that remove HSPGs from the cell surface 
[85]. Owing to its ionic structure, fucoidan mimics some properties of GAGs and can bind and 
modulate the activity of a large number of proteins, including proteases, cytokines and growth 
factors. As a result, fucoidan affects many biological activities in vitro, including coagulation, 
inflammation, viral infection, fertilization, and angiogenesis [7,56,68,98].  
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5.3.3 Fucoidan may act as a direct growth-factor signal transducer 
The proangiogenic activity of fucoidan is linked to its direct interaction with cell membranes. 
Fucoidan binds to the EPC outer membrane at displaceable binding sites, and is then internalized by 
endocytosis. There it can enhance local angiogenesis through the transduction of intracellular signals 
required to induce the proangiogenic phenotype. Endothelial cell surface-bound fucoidan could also 
act as a coreceptor for angiogenic growth factors. The putative fucoidan receptor function might 
involve a carbohydrate-binding domain that interacts with the fucoidan carbohydrate backbone. 
Fucoidan might thus interact with macrophage TLR4 and SR receptors that recognize carbohydrate 
structures [99]. Its binding to these receptors induces several signal transduction events (p38, MAPK, 
ERK1/2 and SAPK/JNK activation) that lead to macrophage activation. Because of its spatial structure, 
fucoidan can mimic the clustering of sulphated, sialylated and fucosylated oligosaccharides on the 
cell surface and can provide the appropriate structural backbone to bind selectins with high affinity 
[100,101]. Fucoidan is also able to interact with other receptors on the cell membrane, such as CD44 
(hyaluronic acid receptor), M (CD11b), 2 (CD18) and even M2 (macrophage antigen-1 (Mac-1)) 
[85].  
Fucoidan binds to the cell membrane and can thereby induce cellular responses analogous to signal 
transduction by growth factors. It is thus able to modulate the expression of genes involved at 
different stages of neovessel formation, such as cell migration, cytoskeleton organization, cell 
mobilization, and homing [102]. 
Pseudotube formation induced by fucoidan correlates in vitro with overexpression of the 6 integrin 
subunit on the endothelial cell surface [83,102]. This 6 overexpression results from transcriptional 
upregulation. The integrin 6 chain, when assembled with integrin 1 or 4 subunits, forms major 
receptors for laminin. Several results show that 6 integrins function in vivo as homing receptors for 
haematopoietic stem cells and progenitor cells [103,104]. The same integrins also promote vascular 
repair. The effect of fucoidan on 6 expression on the cell membrane would strongly enhance stem 
cell migration and mobilization in vivo. HSPGs can transduce extracellular signals in a manner 
analogous to signal transduction by growth factor receptors. Fucoidan may act as a direct signal 
transducer. It is conceivable that membrane-bound fucoidan may participate directly in signal 
transduction in response to growth factor binding, by interacting directly with its receptors. The idea 
that coreceptors may act as signalling molecules independently of their role as receptor binding 
partners is beginning to gain ground.  
5.4 How does fucoidan act in vivo? 
In vivo, fucoidan can bind to numerous proteins. Fucoidan actively modulates coagulation and can 
reduce circulating levels of thrombin by catalysing its inhibition [7,56,57,67,70,75,77]. Lower 
thrombin generation would attenuate thrombus formation, thereby enabling macrophages and EPCs 
to migrate to the lesion and ensure reperfusion. GAGs have a crucial role in mediating stem cell 
recruitment and homing to ischemic tissues. GAGs play a key role in sequestering a variety of 
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proteins that regulate the proliferation, differentiation and trafficking of stem cells between bone 
marrow and peripheral blood.  
Several lines of evidence suggest that fucoidan acts through SDF-1. Intramuscular fucoidan injections 
increase plasma levels of SDF-1 and thus promote stem cell mobilization [47,49,86]. SDF-1 is 
anchored to HSPGs present at the surface of stromal cells and endothelial cells, and on the ECM. 
Fucoidan can specifically displace sequestered SDF-1 from its HSPG anchors on the endothelial 
surface and thereby contribute to its release into the circulation. According to Sweeney, the amount 
of SDF-1 thus released into the circulation is sufficient to trigger the observed cell mobilization [49]. 
In addition to SDF-1, levels of other chemokines (IL-6, IL-8) and cytokines (granulocyte CSF, 
macrophage CSF) are also increased after fucoidan treatment, possibly owing to their release from 
HSPGs.  
In his excellent review of sulphated fucans and galactans, Pomin forwards a mechanism to explain 
the antiinflammatory properties of marine polysaccharides that could also account for the impact of 
fucoidan on EPC recruitment [105]. The molecular mechanisms behind these proangiogenic 
properties would involve (Figure 8): i) impaired binding of stem cells to the endothelium via fucoidan 
binding to P- and/or L-selectins which play a central role in the inflammatory response triggered by 
ischemia (P-selectin is upregulated on endothelial cells and platelets during ischemic disorders) 
[102,106] and, most likely, ii) disruption of the SDF-1 gradient between blood and bone marrow or 
ischemic tissue. This would modify the chemokine gradient that sustains the homing of stem 
cells/leukocytes to ischemic sites and promotes their mobilization. In addition to the contribution of 
EPCs to new vessel formation, enhanced SDF-1 expression, which can activate EPCs, may also 
contribute to revascularization of ischemic tissues [54]. This would also explain the impact of 
fucoidan on intimal growth after stenting in rabbits and after allogeneic vascular transplantation in 
mice [78,92]. Fucoidan can also act on surrounding cells such as smooth muscle cells, neutrophils and 
macrophages attracted by cytokines released from an ischemic site [107].  
During transmigration through the endothelium, progenitors traverse the endothelial cell monolayer 
and the subendothelial basement membrane. Consequently, transmigrating cells interact with 
endothelial cells, GAGs and EMC adhesion proteins. Integrin 6, a laminin receptor involved in stem 
cell homing to bone marrow [104], is expressed by EPCs. Its expression is required for stem cell 
migration, and its overexpression after fucoidan treatment might facilitate their homing towards 
ischemic sites. Finally, adhesion receptors like selectins are important for cell migration and 
extravasation to ischemic sites. During mobilization, traffic between bone marrow and blood is 
bidirectional. According to Frenette et al., blockade of endothelial selectins may prevent progenitors 
from re-entering bone marrow [48].  
6- Conclusion 
Development of a therapy capable of preventing tissue necrosis and of favouring revascularization is 
crucial for patients with critical ischemia [108]. Although marine polysaccharides have numerous 
interesting effects on coagulation, thrombosis, inflammation and angiogenesis, their clinical 
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development is hindered by their heterogeneity. Fucoidan is systemically distributed after ingestion 
or intravenous injection and is non toxic in mice when injected at doses exceeding 1 g/kg (private 
communication). Oral ingestion of fucoidan at doses of 1 to 3 g/day for up to 3 months is non toxic in 
healthy volunteers [93,109].  
Cardiovascular disease is the leading cause of death worldwide (17.3 million deaths each year, 
representing 30% of global mortality), and new anticoagulants are urgently needed. LMW fucoidans 
possess several important advantages as alternative anticoagulant and proangiogenic therapies. First 
and foremost, they are devoid of significant pro-haemorrhagic effects. Second, because of their non-
mammalian origin, there is no risk of contamination with viruses or unconventional pathogens such 
as the prion responsible for bovine spongiform encephalopathy. Third, as byproducts of alginate 
preparation for the food and cosmetics industries, they represent a cheap and readily available 
source of new biologically active molecules. A better understanding of the mechanisms by which 
these polysaccharides promote EPC activation and recruitment to ischemic sites is necessary for 
optimal development of a proangiogenic therapy product.  
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